Johnson & Johnson (NYSE:JNJ) Shares Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on December 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on December 24th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Norfolk Southern (NYSE:NSC) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 12/24/2024.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 12/24/2024.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $143.34 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market cap of $345.11 billion, a P/E ratio of 20.74, a PEG ratio of 2.52 and a beta of 0.51. The company has a fifty day moving average price of $153.32 and a 200 day moving average price of $156.33. Johnson & Johnson has a one year low of $142.75 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the business earned $2.66 earnings per share. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.46%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JNJ. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Bank of America reissued a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $174.73.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JNJ. International Assets Investment Management LLC increased its position in Johnson & Johnson by 20,130.0% in the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after purchasing an additional 3,437,397 shares during the period. Marshall Wace LLP raised its stake in shares of Johnson & Johnson by 506.9% during the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock worth $567,826,000 after buying an additional 3,244,862 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after acquiring an additional 2,356,359 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 10.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company’s stock worth $2,744,979,000 after acquiring an additional 1,831,751 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Johnson & Johnson by 16.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the company’s stock valued at $1,921,565,000 after purchasing an additional 1,829,257 shares during the period. 69.55% of the stock is currently owned by institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2025. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2024 election. Marjorie Taylor Greene earned a bachelor’s degree in business administration from the University of Georgia. Greene’s career experience includes co-owning construction company Taylor Commercial and founding and owning a CrossFit gym.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.